Second, we examined BYF’s therapeutic effect on CKD in vivo. We used an adenine-induced CKD rat model and found that BYF reduced renal fibrosis and inflammation, and simultaneously inhibited the TLR4/NF-κb pathway. The gene discussed is TLR4; the disease is chronic kidney disease.